PIN1 and cancer: Since Pin1 has been suggested as a therapeutic cancer drug target (Zhou and Lu, 2016), and development of more potent and specific Pin1 inhibitors is underway, our data suggest that Pin1-targeting drugs may also be good candidate treatments for chronic HBV and HBV-associated HCC.